Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II study of Diamyd in autoimmune diabetes opens for recruitment

March 4, 2020

Phase I results presented for rongliflozin

March 3, 2020

Visceral adipose inflammation found to be sex-specific

March 2, 2020

Spark Therapeutics opens enrollment in phase I/II study of SPK-3006 in late-onset Pompe disease

Feb. 28, 2020

FDA approves Nexlizet tablet as first non-statin LDL-C lowering combination medicine

Feb. 28, 2020

Inorbit Therapeutics AB synthesizes new NR1H4 agonists

Feb. 26, 2020

Preclinical data presented for scAAV9/CLN7 gene replacement therapy

Feb. 26, 2020

ASOs targeting GYS1 show promise in mouse model of Pompe disease

Feb. 25, 2020

Sojournix begins phase II study of SJX-653 for vasomotor symptoms due to menopause

Feb. 25, 2020

FDA approves Nexletol to lower LDL-C in patients with HeFH or ASCVD

Feb. 24, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...